Ann Muriuki։ How Freeze-Dried Plasma Could Reshape Emergency Trauma Care
Ann Muriuki, Entrepreneur and Life Coach, shared a post on LinkedIn:
“The FDA’s recent approval of freeze-dried plasma marks a significant leap forward in emergency medicine and trauma care.
This innovative product not only extends the shelf life of plasma but also enables rapid deployment in critical situations, which is vital for improving patient outcomes during severe trauma and mass casualty events.
As healthcare providers increasingly face the challenges of time-sensitive interventions, this advancement ensures that they can respond effectively when every second counts.
The ability to have life-saving resources readily available in the field can truly transform the landscape of emergency response.
How might this innovation reshape the protocols and practices in trauma care?”
David McIntosh, Founder and Chair of United Plasma Action, commented on this post on LinkedIn:
“‘How might this innovation reshape trauma care?’ is a great question.
The answer, sadly, as in so many Healthcare cases, globally, is of course – ‘That will depend ….’
It will principally depend upon how far and how fast global plasma supplies can be brought up to at least a genuinely minimum acceptable level – which currently they’re nowhere near.
It will also of course depend – very much – on whether we’re talking here about our priviliged High Income Countries or situations in less fortunate places.
Let’s face it though, with only a handful of countries, worldwide, actually generating a plasma supply adequate to meet their existing needs, the chances of transformational change coming from a new way of using up those scarce resources seem rather slim … don’t they …? ”
Stay updated with Hemostasis Today.
-
Oct 12, 2026, 13:58Francisco Chacón-Lozsán: Catastrophic Antiphospholipid Syndrome A Rapidly Progressive Multiorgan Thrombotic Emergency
-
Oct 12, 2026, 12:50Nawsherwan Mohammad: Study Examines Thrombotic Events in Patients with Polycythemia Vera in Iraq
-
Oct 12, 2026, 12:30Chanakya Nayudu: Looking Beyond Blood Clots – Patient-Reported Outcomes in Antiphospholipid Syndrome
-
Oct 12, 2026, 12:12Jean-Jacques Kiladjian: Improving Treatment Strategies with JAK Inhibitors in Myelofibrosis
-
Oct 12, 2026, 12:04Chloe Homich: AABB Annual Meetings – Building Connections and Advancing Transfusion Medicine
-
Oct 12, 2026, 11:51Daniel Sop: Sickle Cell Research Takes Center Stage at ASCAT 2026
-
Oct 12, 2026, 10:36PAI-1 Inhibition as a New Strategy for Enhancing Fibrinolysis and Clot Resolution
-
Oct 12, 2026, 07:39Emmanuel J Favaloro: 100 Years of von Willebrand Disease and the Importance of Local Diagnosis and Management
-
Oct 12, 2026, 07:39Post-Stroke Fatigue Trajectories – 38% Recovered at 12 Months, While 16% Developed New Fatigue – International Journal of Stroke